Eko Health Raises $41M in Series D Funding


Eko Health, a San Francisco-based digital health company specializing in AI-powered detection of heart and lung diseases, has raised $41 million in Series D funding.

Key Highlights:

  • Funding Amount: $41 million in Series D funding.
  • Investors: ARTIS Ventures, Highland Capital Partners, NTTVC, Questa Capital, Double Point Ventures, EDBI, and LG Technology Ventures.

Company Overview:

  • CEO: Connor Landgraf.
  • Location: San Francisco, CA.
  • Core Focus: Eko Health advances the detection and monitoring of heart and lung diseases using digital stethoscopes, patient and provider software, and AI-powered analysis.

Use of Funds:

  • U.S. Presence: The company aims to deepen its presence in the U.S. market.
  • International Expansion: Accelerate expansion into key international markets.
  • Platform Access: Expand access to its AI-enabled cardiac and pulmonary disease detection platform.

Product and Impact:

  • FDA-Cleared Platform: Eko Health’s platform is FDA-cleared and used by over 500,000 healthcare professionals worldwide.
  • Technological Integration: The platform includes digital stethoscopes and software for patients and providers, integrating AI to enhance diagnostic accuracy.
  • Healthcare Benefits: The technology enables earlier detection, higher accuracy in diagnoses, better treatment management, and improved patient care.

Statements from Leadership:

  • Connor Landgraf, CEO of Eko Health:
    “This funding will enable us to expand our innovative solutions and bring our AI-powered cardiac and pulmonary detection tools to more healthcare professionals globally. We are committed to advancing the early detection and management of heart and lung diseases to improve patient outcomes.”

With the $41 million Series D funding round, Eko Health is set to enhance its market presence in the U.S., expand internationally, and increase access to its AI-enabled disease detection platform. Supported by leading investors, Eko Health continues to revolutionize the early detection and monitoring of cardiac and pulmonary diseases, providing healthcare professionals with advanced tools to deliver better patient care.

Related Stories